These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35908959)

  • 21. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
    Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
    In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
    Mizusawa J; Fukutomi A; Katayama H; Ishii H; Ioka T; Okusaka T; Ueno H; Ueno M; Ikeda M; Mizuno N; Ozaka M; Fukuda H; Furuse J;
    Pancreatology; 2018 Oct; 18(7):841-845. PubMed ID: 30075908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
    Chun JW; Lee SH; Kim JS; Park N; Huh G; Cho IR; Paik WH; Ryu JK; Kim YT
    BMC Cancer; 2021 May; 21(1):537. PubMed ID: 33975561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
    Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
    Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
    Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
    Papneja N; Zaidi A; Chalchal H; Moser M; Tan K; Olson C; Haider K; Shaw J; Ahmed S
    Pancreas; 2019 Aug; 48(7):920-926. PubMed ID: 31180981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
    Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
    Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
    Dai WF; Habbous S; Saluja R; Beca JM; Raphael M; Arias J; Gavura S; Earle CC; Biagi JJ; Coburn N; Chan KKW
    Clin Oncol (R Coll Radiol); 2023 May; 35(5):e303-e311. PubMed ID: 36863956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
    Zhang H; Kellett C; Lambert P; Kim CA
    Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
    Vogl UM; Andalibi H; Klaus A; Vormittag L; Schima W; Heinrich B; Kafka A; Winkler T; Öhler L
    BMC Cancer; 2019 Jan; 19(1):28. PubMed ID: 30621630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
    Chan KKW; Guo H; Cheng S; Beca JM; Redmond-Misner R; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ; Welch S; Meyers BM; Mittmann N; Coburn N; Arias J; Schwartz D; Dai WF; Gavura S; McLeod R; Kennedy ED
    Cancer Med; 2020 Jan; 9(1):160-169. PubMed ID: 31724340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
    Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
    BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy.
    Nishioka M; Okano N; Wakabayashi M; Ikeno T; Hayashi M; Mizutani T; Nagashima F; Furuse J
    Anticancer Res; 2024 Mar; 44(3):1233-1239. PubMed ID: 38423651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
    Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
    Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
    Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
    Arima S; Kawahira M; Shimokawa M; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Taguchi H; Honda T; Shibuki T; Mitsugi K; Nio K; Ide Y; Ureshino N; Mizuta T; Shirakawa T; Otsuka T
    Pancreas; 2021 Aug; 50(7):957-964. PubMed ID: 34347735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
    Ide Y; Otsuka T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Shinohara Y; Ueno S; Taguchi H; Honda T; Shibuki T; Nio K; Ureshino N; Mizuta T; Mitsugi K; Shirakawa T
    Anticancer Res; 2023 Apr; 43(4):1817-1826. PubMed ID: 36974805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
    Cui H; Guan J; Deng G; Yuan J; Lou C; Zhang W; Zhou A; Zhang Y; Zhou J; Dai G
    Med Sci Monit; 2020 Oct; 26():e927654. PubMed ID: 33100319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
    Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM
    BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.